mitochondrial ribosomal protein L27Genealiases: L27mt · bL27m
Q-omics provides the consensus-scored MRPL27 profile across patient tissues and cancer cell-line models. MRPL27 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MRPL27 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MRPL27 protein abundance shows 18,835 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where MRPL27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL27 survival associations across molecular data types. MRPL27 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL27 RNA expression–survival associations across cancer types. High MRPL27 expression shows unfavorable associations in UVM, KICH, SKCM, ACC, HNSC and STAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MRPL27 RNA expression.
This table summarizes MRPL27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL27 shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, BLCA, LUAD and KIRP. The KIRC box plot shows higher MRPL27 RNA expression in tumor versus normal tissue (log2 FC = +0.317, t-test p < 0.001).
This table shows molecular features associated with MRPL27 in patient tissues and cancer cell lines. In patient samples, MRPL27 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
